enGene Therapeutics Inc. Operating Cash Flow
enGene Therapeutics Inc. (ENGN) reported Operating Cash Flow of -$78.35 million for the 9-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-08
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-07-31 was -$18.95M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-04-30 was -$30.50M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-01-31 was -$28.90M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-10-31 was -$24.96M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$99.24M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$48.28M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$24.74M.
- enGene Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$17.59M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$18.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | -$49.44M derived: sum of 2 quarters · filed 2026-09-08 | -$78.35M 10-Q · filed 2026-09-08 | -$103.31M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | -$30.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-15 | -$59.40M 10-Q · filed 2026-06-15 | -$84.36M derived: sum of 3 quarters · filed 2026-06-15 | -$110.00M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | -$28.90M 10-Q · filed 2026-03-09 | -$53.87M derived: sum of 2 quarters · filed 2026-03-09 | -$79.50M derived: sum of 3 quarters · filed 2026-09-08 | -$102.45M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | -$24.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$50.60M derived: sum of 2 quarters · filed 2026-09-08 | -$73.54M derived: sum of 3 quarters · filed 2026-09-08 | -$99.24M 10-K · filed 2025-12-22 |
| 2025-07-31 | -$25.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | -$48.58M derived: sum of 2 quarters · filed 2026-09-08 | -$74.28M 10-Q · filed 2026-09-08 | -$93.84M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | -$22.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-15 | -$48.64M 10-Q · filed 2026-06-15 | -$68.21M derived: sum of 3 quarters · filed 2026-06-15 | -$75.39M derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | -$25.70M 10-Q · filed 2026-03-09 | -$45.26M derived: sum of 2 quarters · filed 2026-03-09 | -$52.45M derived: sum of 3 quarters · filed 2026-03-09 | -$66.61M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | -$19.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$26.75M derived: sum of 2 quarters · filed 2025-12-22 | -$40.91M derived: sum of 3 quarters · filed 2025-12-22 | -$48.28M 10-K · filed 2025-12-22 |
| 2024-07-31 | -$7.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-09-11 | -$21.34M derived: sum of 2 quarters · filed 2025-09-11 | -$28.71M 10-Q · filed 2025-09-11 | -$35.49M derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | -$14.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-06-12 | -$21.53M 10-Q · filed 2025-06-12 | -$28.31M derived: sum of 3 quarters · filed 2025-06-12 | -$35.61M derived: sum of 4 quarters · filed 2025-06-12 |
| 2024-01-31 | -$7.37M 10-Q · filed 2025-03-10 | -$14.15M derived: sum of 2 quarters · filed 2025-03-10 | -$21.45M derived: sum of 3 quarters · filed 2025-03-10 | -$25.89M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | -$6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | -$14.08M derived: sum of 2 quarters · filed 2024-12-19 | -$18.52M derived: sum of 3 quarters · filed 2024-12-19 | -$24.74M 10-K · filed 2024-12-19 |
| 2023-07-31 | -$7.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-09-10 | -$11.74M derived: sum of 2 quarters · filed 2024-09-10 | -$17.97M 10-Q · filed 2024-09-10 | |
| 2023-04-30 | -$4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-06-14 | -$10.67M 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | -$6.22M 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | -$17.59M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |